Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for treatment of third-line or later (3L+) R/R follicular lymphoma (FL): Update with 24 months of liso-cel follow-up (FU).

Authors: Alexander Paul Boardman, Juan Luis Reguera, Pearl Wang, Jenna Ellis, Merav Bar, Jinender Kumar, Thalia Andrea Farazi, Alejandro Martin Garcia-Sancho, Koji Izutsu

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e19049

Source: Full article

---

Abstract

e19049